Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
47.02 USD -0.04% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. +8.09% +678.48%
Jun. 03 Corbus Pharmaceuticals Reaches 2-Year High After Drug Results DJ
Jun. 03 Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating MT

Evolution of the average Target Price on Corbus Pharmaceuticals Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

450aa49fed33.Ky1UXX91mLjTfFKVZuoQBh67b-cUXqk-kVpcaqm0TlY.UVttHE4G1e-UKBbHB4xnbU32Pb5_K-db4xkwBP_fIQ5SFDkCOwTyleobOQ~94d3b9098dc06fe1873e705339a10c7a

Analyst Recommendations on Corbus Pharmaceuticals Holdings, Inc.

Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $80 From $60, Maintains Outperform Rating MT
RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating MT
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating MT
Oppenheimer Upgrades Corbus Pharmaceuticals to Outperform From Perform, $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
47.02 USD
Average target price
77.67 USD
Spread / Average Target
+65.18%
High Price Target
80 USD
Spread / Highest target
+70.14%
Low Price Target
76 USD
Spread / Lowest Target
+61.63%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corbus Pharmaceuticals Holdings, Inc.

Oppenheimer
RBC Capital Markets
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. Consensus Corbus Pharmaceuticals Holdings, Inc.